Diabetes, hypertension and dyslipidemia medication prescribing in Qatari primary care settings: a retrospective analysis of electronic medical records
Tóm tắt
Globally, non-communicable diseases (NCDs) are recognised as a leading cause of morbidity and mortality. Medications and medicines optimisation play an important role in the management of modifiable physiological risk factors and NCDs. The importance of lifestyle interventions in prevention of modifiable risk factors is also well established. The aim of this paper was to describe the quantity of type 2 diabetes mellitus (T2DM), hypertension and dyslipidaemia prescribing in Qatari primary care settings. Its findings will provide necessary information to inform pharmaceutical policy and practice. The study was undertaken in Qatar’s publicly funded primary health care centres. Data sources for this study comprised electronic medical records. The Anatomical Therapeutic Chemical (ATC) drug classification system was used to classify the medications prescribed. The number and proportion of medications by age, sex, nationality and diagnosis (T2DM, hypertension and dyslipidaemia) were reported. A total 81,569 individuals were included (18–29 years 2.4%; 30–39 years 11.7%; 40–49 years 25.4%; 50–59 years 31.9% and ≥ 60 years 28.6%). 55.6% participants were male. On average 10.2 medications were prescribed per person and 2.3 medications were included in each prescription. T2DM medications were most prescribed (N = 361,87780,799; 43.2%) followed by hypertension (N = 303,086; 36.2%) and dyslipidaemia (N = 172,163; 20.5%). Of the total medications prescribed, 72% (N = 605,488) were prescribed in individuals aged 50 years and above. Men were prescribed 62% (N = 515,043) medications while women were prescribed 38% (N = 322,083) medications. Southern Asians (N = 330,338; 39%) were prescribed most medication followed by Qataris (N = 181,328; 22%) and Northern African (N = 145,577; 17%). In Qatar’s primary care settings, average medications prescribed per patients were found to be higher compared to other populations. While medications were actively prescribed for the 3 conditions, the study found variations by medication type, age, gender and nationality. Rational guidelines for the utilisation of medications need to be established with the support of real-world evidence.
Tài liệu tham khảo
Widyahening IS. The role of primary health care in the prevention of noncommunicable diseases. Rev Prim Care Prac and Educ. 2019;2(1):5–7.
Royal Pharmaceutical Society. Medicines Optimisation:Helping patients to make the most of medicines Available from https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Policy/helping-patients-make-the-most-of-their-medicines.pdf. Accessed 06 June 2021.
Garfield S, Barber N, Walley P, et al. Quality of medication use in primary care—mapping the problem, working to a solution: a systematic review of the literature. BMC Med. 2009;7:50. https://doi.org/10.1186/1741-7015-7-50.
National Institute for Health and Care Excellence. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. NICE guidelines [NG5], 2015.
NHS England. Medicines optimisation. Available from https://www.england.nhs.uk/medicines-2/medicines-optimisation/. Accessed 06 June 2021.
Syed MA, Alnuaimi AS, Zainel AJ, et al. Prevalence of non-communicable diseases by age, gender and nationality in publicly funded primary care settings in Qatar. BMJ Nutr Prev Health. 2019. https://doi.org/10.1136/bmjnph-2018-000014.
Syed MA, Alnuaimi AS, Zainel AJ, et al. Prevalence of Metabolic Syndrome in Primary Health settings in Qatar: a cross sectional study. BMC Public Health. 2020;20:611. https://doi.org/10.1186/s12889-020-08609-5.
Davis JC, Verhagen E, Bryan S, et al. 2014 consensus statement from the first Economics of Physical Inactivity Consensus (EPIC) conference (Vancouver). Br J Sports Med. 2014;48(12):947–51. https://doi.org/10.1136/bjsports-2014-093575.
Ezzati M, Riboli E. Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals. Science. 2012;337(6101):1482–7. https://doi.org/10.1126/science.1227001.
Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors to achieving the 25x25 non-communicable disease mortality reduction target: a modelling study. Lancet. 2014;384(9941):427–37. https://doi.org/10.1016/s0140-6736(14)60616-4.
WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD): World Health Organization 2003 [cited 2020 10/03/2020]. https://www.who.int/standards/classifications/other-classifications/the-anatomical-therapeutic-chemical-classification-system-with-defined-daily-doses. Accessed 06 June 2021.
Hagstrom B, Mattsson B, Wimo A, et al. More illness and less disease? A 20-year perspective on chronic disease and medication. Scand J Public Health. 2006;34(6):584–8. https://doi.org/10.1080/14034940600703407.
Alsuwaidan A, Almedlej N, Alsabti S, et al. A comprehensive overview of polypharmacy in elderly patients in Saudi Arabia. Geriatrics. 2019;4:2. https://doi.org/10.3390/geriatrics4020036.
Rahim HF, Sibai A, Khader Y, et al. Non-communicable diseases in the Arab world. Lancet. 2014;383(9914):356–67. https://doi.org/10.1016/s0140-6736(13)62383-1.
Al Rasadi K, Almahmeed W, AlHabib KF, et al. Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis. 2016;252:182–7. https://doi.org/10.1016/j.atherosclerosis.2016.07.925.
Al-Maatouq M, Al-Arouj M, Assaad SH, et al. Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin. Int J Clin Pract. 2010;64(2):149–59. https://doi.org/10.1111/j.1742-1241.2009.02235.x.
van den Akker M, Vaes B, Goderis G, et al. Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015. PLoS ONE. 2019;14(2):e0212046. https://doi.org/10.1371/journal.pone.0212046.